Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (Aspylori)

This study has been terminated.
(no inclusion)
Sponsor:
Information provided by:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00713947
First received: June 18, 2008
Last updated: October 11, 2010
Last verified: October 2010
  Purpose

Low dose of aspirin is the main cause of gastro-duodenal ulcer. The best prevention is not definite particularly in patients without history of ulcer and infected by H. pylori.The aim of the study is to evaluate the gastric damage induced by aspirin in patients with H. pylori infection but who have any history of ulcer.


Condition Intervention Phase
Positive Helicobacter Pylori Serology
Coronary Thrombosis
Supra-Aortic Artery Thrombosis
Drug: during one week for the active treatments
Drug: Pantoprazole
Drug: Placebo Formula 515
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Measure: severity of the ulcerated gastric lesions induced by the aspirin [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To measure: percentage of patients having had at least an ulcer [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • To measure: the average of the ranks of lesion in antrum and corpus. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • To measure percentage of patients having had digestive clinical events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • To measure: the average of the ranks of severity of the hemorrhagic lesions and erosive lesions evaluated in antrum and corpus by two analogical scales of 150 mm [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • To measure Percentage of patients having a hemorrhagic digestive of clinical expression or detected by the biological tests. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • To measure : Elements of the histopathologic score of Sydney [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Enrollment: 0
Study Start Date: April 2008
Study Completion Date: March 2010
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
Drug: during one week for the active treatments
during one week for the active treatments placebo during 25 weeks
Other Names:
  • Amoxicillin
  • Clarythromycin or metronidazole
  • Pantoprazole
  • Placebo
Experimental: B
Pantoprazole
Drug: Pantoprazole
6 months at 20 mg
Other Name: Pantoprazole
Placebo Comparator: C
Placebo
Drug: Placebo Formula 515
26 weeks, one tablet per day
Other Name: Placebo Formula 515

Detailed Description:

The aim of the study is to compare the protective effect of H. pylori eradication versus Pantoprazole versus placebo on the gastric damage induced by low dose of aspirin. Treatment are attributed by randomisation. Patients are followed for 6 months and gastric damage are evaluated by endoscopy at the end of this period.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients of more than 18 years old
  • Coronarography or coronary imaging or supra-aortic arterial trunks ultrasound examination performed since less 7 months and having at least an arterial vascular stenosis
  • Indication for aspirin treatment for at least 12 months (at the moment of the visit of inclusion) at a posology from 80 to 125 mg per day. The treatment must be prescribed since less than 7 months.
  • Patient who had since less 7 month a positive Helicobacter Pylori serology.
  • For the women in age to procreate, effective mode of contraception (oral contraception, surgical sterilization, coil)
  • Patient having given an informed consent according to recommendation of the CPP (institutional ethical committee).

Exclusion Criteria:

  • treatment by anti-coagulant, whatever its nature and its posology, by proton pump inhibitor, H2 receptor antagonists or antiacid having to be continued beyond the day of inclusion
  • Treatment by methotrexate in progress or stopped since less 3 months.
  • Time of more 7 months enters the beginning of the treatment by aspirin and the visit of inclusion
  • Treatment by NSAID (even occasional or self medication) under or stopped since less 3 months.
  • Treatment by anti-platelet drug (clopidogrel, ticlopidine, flurbiprofen, dipyridamole or antagonist of receptor GPIIb/IIIa) in progress or stopped since less than 10 days.
  • Patient with a serious pathology compromising survival in the 6 month to come.
  • Patient with renal or respiratory insufficiency or a hepatic pathology having a clinical repercussion.
  • History of surgery of esophagus, stomach or duodenum.
  • History of digestive tract bleeding or gastro-duodenal ulcer or esophagal ulcerating proven by endoscopy.
  • Allergy known to clarithromycin.
  • Psychiatric disorder not controlled by treatment.
  • Patients all ready include in a therapeutic protocol or to be followed for 6 month.
  • Alcohol consumption higher than 100gr. per day.
  • Patient non suitable for participating in the protocol or to be followed for 6 month.
  • History of intolerance to salicylate.
  • Constitutional or acquired hemorrhagic disease
  • Pregnant woman or nursing.
  • Patient in emergency, people hospitalized without their assent, people without freedom, people without social health insurance.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00713947

Locations
France
Hotel Dieu Hospital
Paris, France, 75181
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Dominique Lamarque, MD, PhD Assistance Publique - Hôpitaux de Paris
  More Information

No publications provided

Responsible Party: Cécile Kedzia, Department Clinical Research of Developpement
ClinicalTrials.gov Identifier: NCT00713947     History of Changes
Other Study ID Numbers: P051021, AOM 05114
Study First Received: June 18, 2008
Last Updated: October 11, 2010
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Gastric lesions induced by low dose of aspirin
Helicobacter pylori

Additional relevant MeSH terms:
Coronary Thrombosis
Thrombosis
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Embolism and Thrombosis
Vascular Diseases
Amoxicillin
Clarithromycin
Metronidazole
Pantoprazole
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antiprotozoal Agents
Antiparasitic Agents
Radiation-Sensitizing Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors

ClinicalTrials.gov processed this record on August 01, 2014